CRISPR-Cas13a RNA Detection for Early HIV and HCV Self-Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV and HCV detection methods, particularly self-testing and laboratory-based nucleic acid testing, suffer from long detection windows and require laboratory access, leading to false-negative results and limited at-home testing capabilities, which hinders early detection and treatment.
Innovation Solution
Utilizing Cas13a protein and CRISPR guide RNA (crRNA) to directly detect and quantify HIV or HCV RNA without reverse transcription, forming cleavage products that are then detected using a fluorescence detector.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If laboratory-based nucleic acid testing (NAT) is used for HIV detection, then detection sensitivity and early detection capability are improved, but device complexity and requirement for laboratory access increase
Solution Approach 1:
The patent extracts the essential detection function from the complex laboratory-based NAT system and isolates it into a simplified field-deployable assay. The CRISPR-Cas13a system is extracted to perform RNA detection without requiring full laboratory infrastructure, thereby maintaining sensitivity while reducing device complexity and access requirements.
Solution Approach 2:
The patent replaces the complex mechanical and instrumental systems required for laboratory NAT with a biochemical assay based on CRISPR-Cas13a ribonucleoprotein complexes. This substitution eliminates the need for sophisticated laboratory equipment while maintaining detection capability, allowing testing in field settings.
2Ease of operation
If serology-based self-testing is used for HIV detection, then ease of operation and at-home testing capability are improved, but detection window and reliability deteriorate
Solution Approach 1:
The patent changes the detection parameter from antibody presence (serology) to viral RNA detection using CRISPR-Cas13a. This parameter change enables detection during the acute infection window when antibodies are not yet present, while maintaining the simplicity of self-testing. The assay detects HIV RNA directly, extending the detection window to cover the acute phase.
Solution Approach 2:
The patent creates a universal detection system that can identify different HIV infection stages (acute and chronic) through a single assay mechanism. The CRISPR-Cas13a system detects viral RNA regardless of antibody status, providing multi-functional detection capability in a single test that maintains both ease of operation and reliability across different infection phases.
3Measurement precision
If frequent NAT-based testing is performed for chronically infected individuals, then detection accuracy is improved, but loss of time and convenience deteriorate
Solution Approach 1:
The patent enables self-service testing for chronically infected individuals using the CRISPR-Cas13a assay. The simplified test can be performed at home without requiring laboratory visits, allowing individuals to monitor their own viral load accurately. This eliminates the time loss associated with frequent trips to the laboratory while maintaining detection accuracy.
4Reliability
If current state-of-the-art HIV-1 diagnostics are used, then detection reliability is improved, but device complexity and portability deteriorate
Solution Approach 1:
The patent extracts the core detection function from complex laboratory diagnostics and implements it in a portable field-deployable assay. The CRISPR-Cas13a system is extracted to provide reliable HIV-1 detection without requiring laboratory infrastructure, thereby maintaining reliability while improving portability and reducing device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables sensitive, easy-to-handle, and at-home detection of HIV and HCV RNA, reducing detection windows and providing accurate results without the need for laboratory equipment.
Implementation Method 1
incubating a sample containing RNA with a Cas13a protein and at least one CRISPR guide RNA (crRNA) for a period of time sufficient to form one or more HIV or HCV RNA cleavage product(s)
Implementation Method 2
detecting level(s) of HIV or HCV RNA cleavage product(s) with a detector
Data Source
AI summary
The present disclosure relates to methods using CRISPR-Cas13a enzyme, complexed with HIV or HCV crRNAs to specifically and sensitively detect and quantify the presence of HIV or HCV RNA in a sample. These methods can be used to diagnose HIV or HCV infection, quantify the concentration of HIV or HCV RNA present in a sample, identify the presence of different HIV or HCV splice variants, subtypes, or mutations, and to monitor reactivation of HIV or HCV transcription.